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        There are many molecular subsets of human 
high-density lipoproteins (HDLs) that are dis-
tinguished by diff  erences in their lipid and pro-
tein composition. Apolipoprotein A-I (apoA-I) 
is the defi  ning component of all HDLs, which, 
along with diff  erent combinations of proteins, 
confer many functions to HDLs, the best known 
being atheroprotection (  1  ). Trypanosome lytic 
factors (TLFs 1 and 2) are a subset of HDLs that 
contain two unique protein components, hap-
toglobin-related protein (Hpr) (  2  ) and apolipo-
protein L-I (apoL-I) (  3  ). TLF1 is a 500-kD 
lipid-rich HDL particle and TLF2 is a lipid-
poor HDL that circulates in blood as an immuno-
complex with polyclonal IgM (  4, 5  ). 
  TLF is the major innate defense mechanism 
by which humans and certain primates kill the 
majority of trypanosome species; the two sub-
species of trypanosomes that are resistant to lysis 
by TLF infect humans (  6  ). Trypanosome sub-
species expressing the serum resistance  –  associated 
protein (SRA), either naturally (  Trypanosoma 
brucei rhodesiense  ) or via genetic modifi  cation 
(  Trypanosoma brucei brucei-SRA  ), are resistant to 
lysis by TLF (  3  ) because SRA purportedly binds 
apoL-I and neutralizes TLF activity or redirects 
TLF intracellular traffi   cking to prevent lysis 
(  3, 7  ). Tantalizingly, a truncated form of apoL-I 
(Tr-apoL-I) devoid of the SRA-interacting 
domain, which was expressed in bacteria or 
conjugated to nanobodies that recognize a com-
mon carbohydrate epitope on the variant sur-
face glycoprotein (VSG) coat of trypanosomes, 
was reported to escape binding of SRA and kill 
TLF-resistant trypanosomes (  3, 8  ). Although it 
is possible to imagine that transgenic cattle ex-
pressing this Tr-apoL-I could resist infection 
by all trypanosome subspecies, this activity has 
not been examined. 
  Although not infective to humans,   T. b. brucei 
  infects economically important African cattle spe-
cies because they do not make TLFs. This parasite 
can be killed in vitro by human plasma, purifi  ed 
TLF, or recombinant apoL-I by a pore-forming 
mechanism (  9, 10  ). Early reports indicated that 
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plasmids (Tg-Hpr/apoL-I) or coexpress them from a single 
plasmid (Tg-Hpr:apoL-I), which allows protein synthesis in 
the same transfected cell. These results suggest that in vivo 
apoL-I is the main lytic component of TLF. 
  Tg-apoL-I mice mimic humans in their resistance and 
sensitivity to infection with a variety of trypanosome species 
(  Table I  ). Nonprimate mammals do not have the genes that 
encode for Hpr and apoL-I, and therefore they do not produce 
TLF. They are thus susceptible to a broader range of trypano-
some species than humans, such as   T. congolense  ,   T. evansi  , 
purifi  ed Hpr was trypanolytic in vitro (  11  ), but more recent 
data indicate that Hpr cooperates to increase the lytic activity 
of TLF1 (  12  ) or to increase the uptake of TLF1 (  13  ) via an 
Hp/Hpr receptor on trypanosomes (  11, 14  ). Both mecha-
nisms are currently proposed to be instrumental in the level of 
TLF activity in vitro, with the fi  nding that hemoglobin must 
be bound to Hpr to generate an increase in both lytic capacity 
and the receptor-mediated uptake of TLF (  15  ). 
    RESULTS AND DISCUSSION   
  Creation of TLF mice using hydrodynamic-based 
gene delivery 
  To elaborate on the role of Hpr, apoL-I, and Tr-apoL-I and 
to explore reconstitution of TLF activity in vivo, we created 
a physiologically relevant system that allows transgenic ex-
pression of individual or multiple TLF components in a mouse. 
Using a hydrodynamic gene-based delivery approach (  16  ), 
we generated Tg mice that express native human Hpr, apoL-I 
or Tr-apoL-I, or both components predominantly from the 
liver (  17  ), which is the normal site where TLF components 
are synthesized and assembled. Expression plasmids that encode 
Hpr and/or apoL-I or Tr-apo L-I are expressed and proteins 
are secreted into the circulation within 24 h. 
  Human TLF has several well-characterized properties that 
defi  ne it as a specifi  c subset of HDL. We used the following 
criteria as a benchmark for comparing the activity of reconsti-
tuted TLFs from Tg mice: (a) coimmunoprecipitation experi-
ments have revealed that Hpr and apoL-I are coexpressed in 
the same particle despite constituting only 1% of HDL mole-
cules, suggesting that their distribution in HDL particles is 
nonrandom (  12, 15  ). (b) Trypanolytic activity of human 
plasma or purifi  ed TLF against   T. b. brucei   can be demon-
strated in an in vitro killing assay during which the trypano-
somes swell and burst. Alternatively, human plasma can be i.v. 
injected into a mouse to provide protection against   T. b. brucei   
infection (  18  ). (c) Trypanosomes that express SRA either nat-
urally (  T. b. rhodesiense  ) or artifi  cially (  T. brucei-SRA  ) are resis-
tant to trypanolysis by TLF in vitro (  3  ) or in vivo after transfer 
of human plasma or purifi  ed TLF i.v. to mice (  18  ). (d) Trypa-
nolytic activity in vitro can be blocked by addition of weak 
bases to prevent acidifi  cation of internal vesicles, which is re-
quired to activate TLF after uptake and internalization of the 
lipoprotein particle by the parasite (  19  ). 
  Apolipoprotein L-I protects mice from infection 
with   T. b. brucei  ,   T. evansi  , and   T. congolense   
  Tg mice expressing genes that encode for Hpr and apoL-I in-
dividually reveal that only mice expressing the apoL-I trans-
gene (Tg-apoL-I) are protected from challenge with   T. b. 
brucei  . In contrast, mice that express the Hpr transgene (Tg-
Hpr) are not protected and succumb to infection with the 
same kinetics as mice given the empty vector (  Fig. 1 A  ). We 
then evaluated whether the expression of Hpr and apoL-I to-
gether in vivo would give additional protection beyond that 
seen with apoL-I. There is no increase in protection when 
the mice express both Hpr and apoL-I either from individual 
    Figure 1.     Survival kinetics of mice infected with   T. b. brucei   ILTat 1.25, 
relative lytic units, and protein expression in Tg mice.   (A) Mice expressing 
Hpr (black diamond;   n   = 13), apoL-I (black square;   n   = 13), or a combina-
tion of Hpr and apoL-I in individual plasmids (white triangle; Hpr/apoL-I; 
  n   = 10) or in a single plasmid (black circle, Hpr:apoL-I;   n   = 6) were infected 
i.p. with 1.78   ×   10  6   trypanosomes. Control mice were treated with empty 
vector (gray circle;   n   = 14). The parasitemia was monitored and time of 
death was recorded. (B) Survival kinetics of naive mice infected with   T. b. 
bruce  i ILTat 1.25 that were administered plasma i.v. from mice transfected 
with empty vector (gray circle;   n   = 7), apoL-I (black square;   n   = 7), or a 
combination of Hpr and apoL-I in a single plasmid (black circle; Hpr:apoL-I; 
  n   = 3). The protection obtained by normal human plasma (dilution 1/8) is 
indicated by the inverted triangle. (C) Western blot with serial dilutions of 
plasma from Tg mice expressing murine apoA-I and human Hpr and apoL-I 
from the same plasmid (Hpr:apoL-I) and Tg mice expressing human apoA-I 
and human Hpr and apoL-I from the same plasmid (Hpr:apoL-I). Hpr and 
apoL-I were detected with monoclonal antibodies.     JEM VOL. 205, August 4, 2008  1723
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survival 192 h) confer equal protection, which indicates that 
coexpression of Hpr in the context of murine HDL does not 
increase lytic activity. 
  Transfer of 300   μ  l human plasma completely cleared the 
trypanosome infection and protected the mice indefi  nitely. 
To gauge the relative amount of lytic units within the plasma 
from diff  erent Tg mice, we serially diluted human plasma 
until survival time was     300 h (1:8, 37   μ  l;   Fig. 1 B  ). In this 
plasma transfer assay, we fi  nd that Tg mouse plasma has     10% 
the lytic capacity of normal human plasma. In contrast to 
human plasma, Tg-apoL-I plasma or Tg-Hpr:apoL-I plasma 
showed no trypanolytic activity in vitro within the time frame 
of our standard assay (unpublished data), which suggests that 
the Tg plasma is missing some additional human component 
that augments or stabilizes activity in vitro or in vivo  .   
  Human apoA-I and haptoglobin-related protein increase 
the specifi  c activity of HDL synthesized by Tg mice 
  We next evaluated whether human apoA-I could augment or 
stabilize the Tg-TLF activity in vitro or in vivo. In contrast to 
mice, humans have three major HDL subfractions designated 
HDL1     11.4 nm, HDL2     10.2 nm, and HDL3     8.7 nm. 
Mice containing a stably integrated human apoA-I transgene 
(HuapoA-I) express     2 mg/ml human apoA-I and 0.1 mg/ml 
murine apoA-I and exhibit a humanlike HDL profi  le of HDL2 
and HDL3, indicating that the amino acid sequence of apoA-I is 
a determinant of the HDL distribution (  20  ). Plasma from Hua-
poA-I mice transfected with Hpr and apoL-I (Hpr:apoL-I) dis-
play similar levels of protein either compared with plasma from 
MuapoA-I mice transfected with Hpr and apoL-I (  Fig. 1 C  ) 
or compared with human plasma (  Fig. 2 A  ), corresponding to 
    5-10   μ  g/ml of apoL-I (  21  ) and     20  –  30   μ  g/ml of Hpr (  22  ). 
  In contrast to the murine apoA-I plasma transfer experi-
ments, we fi  nd that expression of apoL-I in the presence of 
human apoA-I results in plasma that is less lytic than that ob-
tained when both TLF components (Hpr:apoL-I) are expressed. 
Plasma transfer from HuapoA-I mice transfected with Hpr to 
naive mice infected with   T. b. brucei   show no protection by 
Hpr (median survival 32 h), equivalent to vector alone (median 
survival 39.5 h;   Fig. 2 B  ). 
  Plasma from HuapoA-I:Hpr:apoL-I transferred to naive 
mice infected with   T. b. brucei   has an increase in lytic capacity 
(median survival time 288 h) compared with that observed with 
HuapoA-I:apoL-I (median survival 101 h;   Fig. 2 B  ). These data 
reveal that coexpression of Hpr in the context of human apoA-I 
increases lytic activity, which suggests that human apoA-I may 
augment or stabilize Tg-TLF (Hpr:apoL-I) activity in vivo. 
Despite an increase in activity, the triple Tg mouse plasma 
(HuapoA-I:Hpr:apoL-I) is not as potent as human plasma in 
transfer experiments. Additional factors present in human 
plasma, such as TLF2, which is an immune complex of poly-
clonal IgM and lipid-poor TLF1 that circulates in plasma at 
    10   μ  g/ml (  4  ), could explain the diff  erence in lytic capacity. 
  To evaluate the assembly of Hpr and apoL-I into HDLs 
and the lytic capacity of our various Tg mice, we purifi  ed all 
of the diff  erent Tg-HDLs containing human apoA-I by density 
and   T. b. brucei  , which limits their survival in Central Africa. 
  T. congolense   and   T. evansi   are both trypanosomes whose course 
of infection is mild and prolonged because of relapsing but 
ultimately lethal parasitemias, whereas the   T. b. brucei   used in 
these experiments has a short course of infection that is rap-
idly lethal. We show that Tg-apoL-I mice can ameliorate in-
fections with all these trypanosome species and fi  nd that all 
Tg-apoL-I survivors are parasite-free 20 d after infection 
(  Table I  ). As expected, Tg-apoL-I mice infected with   T. brucei-
SRA   were unable to control the parasitemia, and all mice 
succumbed to infection within 3 d with kinetics identical to 
mice that received the empty vector (  Table I  ). 
  Transgene expression decreases with time in the Tg mice; 
blood levels of apoL-I begin to decrease around day 14 and Hpr 
levels begin to decrease around day 7, but low levels of protein 
can still be detected by day 45 (unpublished data). Conse-
quently, we sometimes observe a recrudescence of parasites at 
20  –  25 d after infection, which can develop into a highly lethal 
parasitemia (10  9  /ml). If there is no detectable parasitemia by 
day 25 in the Tg mice, they will remain parasite-free indefi  -
nitely. These parasites that recrudesce are not resistant to TLF, 
and we therefore conclude that some parasites are in tissue 
spaces to which TLF has no access, or that the TLF titer is in-
adequate to kill all of the trypanosomes. 
  Although Tg-apoL-I mice exhibit many of the properties 
of human TLF, experiments in which killing activity was 
assessed by plasma transfer to naive mice indicate that ex-
pression of apoL-I gives lower trypanolytic activity than that 
observed for human plasma. Transfer of 300   μ  l of Tg-apoL-I 
plasma to naive mice already infected with   T. b. brucei   de-
layed the time to peak parasitemia (10  9  /ml) with a median 
survival of 201 h (  Fig. 1 B  ). Despite the variability in the 
plasma transfer assay it is clear that plasma from both Tg-
apoL-I (median survival 201 h) and Tg-Hpr:apoL-I (median 
    Table I.        Transgenic mice that express the apoL-I gene 
ameliorate infection with   T. brucei ,   T. evansi  , and   T. congolense  
Transgenic 
  DNA
Trypanosome species 
  (1.78   ×   10  6   injected 
i.p.)
Number mice alive/ 
  number mice infected
Day 3 Day 20 Day 50
ApoL-I 
  Vector
  T. brucei 
0/5  a 
5/5 3/5  b 
ApoL-I 
  Vector
  T. brucei SRA 0/5a
0/5  a 
ApoL-I 
  Vector
  T. evansi 5/5 
  5/5
4/5  c   
  1/5  d 
ApoL-I 
  Vector
  T. congolense 5/5 
  2/5
3/5  b   
  2/5  d 
Mice expressing the gene for apoL-I were infected with 1.78   ×   10  6    T. b. brucei   (Lister 
427-derived line),   T. b. brucei-SRA   (Lister 427-derived line expressing the SRA gene), 
  T. evansi   (AnTat 3), or   T. congolense   (STIB 68Q).   n   = 5 per group.
  a  Parasitemia   ≥   1   ×   10  9   before mice were killed.
  b  No parasites detectable.
  c  Died of unknown cause, did not have detectable parasites.
  d  Parasitemia = 1   ×   10  6 /  ml.1724 RECONSTITUTION OF TLF IN TRANSGENIC MICE   | Molina-Portela et al. 
gradient ultracentrifugation followed by size fractionation 
and analyzed each fraction by Western blot for localization of 
Hpr, apoL-I, and apoA-I. Size fractionation of lipoproteins of 
the HuapoA-I mice show a broad HDL peak (plain lines, 
#10-14;   Fig. 2 C  ), which matches the distribution of human 
HDL (dashed line). When mice were transfected with a plas-
mid that encodes for Hpr, we fi  nd that Hpr-HDL is enriched 
in fractions 11 and 12 (  Fig. 2 D  ). When mice were trans-
fected with a plasmid that encodes for apoL-I, we fi  nd that 
apoL-I-HDL is enriched in fractions 12 and 13 (  Fig. 2 D  ). 
When we transfected a single plasmid that encodes both 
genes under the control of individual promoters to drive ex-
pression in the same cell, we fi  nd that apoL-I has been   “  re-
distributed  ”   upon coexpression with Hpr predominantly into 
fractions 11 and 12 (  Fig. 2 D  ). This suggests that when co-
expressed, Hpr and apoL-I localize to the same HDL particle 
(Fig. S1, available at http://www.jem.org/cgi/content/full/
jem.20071463/DC1). We observe a similar redistribution of 
apoL-I upon coexpression of Hpr in murine apoA-I HDLs 
(unpublished data). 
  Purifi  ed human TLFs containing either Hpr or apoL-I 
have low specifi  c activities for in vitro trypanolysis relative to 
TLFs that contain both Hpr and apoL-I in the same particle 
(  12  ). Notably, in our experimental system, only the purifi  ed 
triple Tg-HDL, which is composed of HuapoA-I:Hpr:apoL-I, 
showed trypanolytic activity in vitro within the time frame of 
our standard assay (  Fig. 2     E  ). The lytic capacity of the triple 
Tg-HDL was equivalent to that of human TLF-enriched HDL 
(both isolated by the same method). In addition, trypanosome 
lysis by both HDLs was inhibited by incubation of trypano-
somes with ammonium chloride (10 mM), a lyso  somotropic 
agent that blocks the acidifi  cation of internal organelles (  Fig. 
2 E  ). This indicates that we have created a functional Tg TLF 
(HuapoA-I:Hpr:apoL-I) that mimics the properties of human 
TLF. These data reveal that human apoA-I contributes to an 
increase in activity of Tg-Hpr:apoL-I HDLs (but not of Tg-
apoL-I) that is measurable in plasma transfer experiments in 
vivo (  Fig. 2 B  ), and more so in lytic assays in vitro (  Fig. 2 E  ). 
There was no measurable activity in mouse apoA-I:Hpr:apoL-I 
HDL in vitro (unpublished data). Therefore, we conclude that 
the increase in specifi  c activity observed previously in vitro (  13  ) 
is caused not only by the presence of just Hpr and apoL-I, but 
by an interaction between the three human proteins apoA-I, 
Hpr, and apoL-I (  Fig. 2, B and E  ). 
  The diff  erence in the specifi  c activity of the Tg-HDLs 
could arise from changes in the assembly and stability of the 
    Figure 2.     Increased specifi  c activity of Tg-HDL in the presence of 
human apoA-I and Hpr.   (A) Western blot with serial dilutions of plasma 
from HuapoA-I mice expressing Hpr and apoL-I from a single plasmid 
(HuapoA-I:Hpr:apoL-I) and normal human plasma. Hpr and apoL-I were 
detected with monoclonal antibodies. (B) Survival kinetics of naive mice 
infected with   T. b. bruce  i ILTat 1.25 and then given 300   μ  l plasma i.v. from 
HuapoA-I mice expressing Hpr (black diamond;   n   = 3), apoL-I (black 
square;   n   = 3), or both Hpr and apoL-I from a single plasmid (black circle, 
Hpr:apoL-I;   n   = 3). The protection obtained by normal human plasma 
(dilution 1/8) is indicated by the inverted triangle. (C) A  280   profi  le of KBr-
purifi  ed lipoproteins from human (dashed line) and HuapoA-I mouse plasma 
expressing Hpr:apoL-I (red line), Hpr (green line), and apoL-I (blue line) 
separated by size on a Superdex 200 column; fractions 6  –  7 are void, fractions 
8  –  9 are human LDL, fractions 10  –  14 are HDLs, and fraction 15 is albumin. 
(D) Western blot of different size-fractionated lipoproteins from HuapoA-I 
mice expressing Hpr only (HuapoA-I:Hpr), apoL-I only (HuapoA-I:apoL-I), 
or Hpr and apoL-I from the same plasmid (HuapoA-I:Hpr:apoL-I). Hpr and 
apoL-I were detected with monoclonal antibodies. (E) In vitro lytic activity 
of size-fractionated HDL (fraction 11) from human and HuapoA-I mice 
expressing Hpr, apoL-I, or both from a single plasmid (dark gray bars). Open 
bars represent the lytic activity obtained in the presence of NH  4  Cl (10 mM). 
Data show the mean and SEM of fi  ve independent measurements.    
 JEM VOL. 205, August 4, 2008  1725
BRIEF DEFINITIVE REPORT
HDL complex or changes in the traffi   cking of Tg-HDLs in the 
trypanosome. We do not detect any diff  erences in the assem-
bly of TLFs generated with mouse or human apoA-I based on 
the following observations. Hpr and apoL-I are exclusively 
found associated with HDL. We consistently fi  nd redistribution, 
and sometimes an increase, in concentration of apoL-I upon 
coexpression with Hpr. This suggests that there is an interac-
tion of Hpr with apoL-I. Purifi  cation of the Tg-Hpr:apoL-I 
HDLs by KBr ultracentrifugation and size chromatography 
gave equivalent yields of Hpr and apoL-I (unpublished data). 
This suggests that there was no loss of protein components 
during the purifi  cation of TLFs generated with mouse or hu-
man apoA-I. Given that no diff  erence in the relative binding 
to trypanosomes of purifi  ed human HDL subclasses containing 
either Hpr or apoL-I or both Hpr and apoL-I has been re-
ported (  12  ), we hypothesize that human apoA-I in the pres-
ence of Hpr and apoL-I eff  ects either the traffi   cking of the 
purifi  ed triple Tg HDL or the resistance to trypanosomal pro-
teases within the lysosome in agreement with others (  23  ). 
  Apolipoprotein L-I devoid of the   “  SRA-interacting domain  ”   
does not protect mice from trypanosome infection 
  Having established that transient transgenesis provides the 
fi  rst animal model capable of validating reconstituted TLF ac-
tivity in vivo, we next assessed the trypanolytic potential of 
a truncated apoL-I devoid of the SRA-interacting domain 
(Tr-apoL-I). Full-length apoL-I can kill   T. brucei  , but not 
  T. brucei   that expresses SRA. Tr-apoL-I, which is constructed 
by deletion of the C-terminal     -helix starting at amino acid 
340, has been synthesized in bacteria and cell-free systems and 
is reported to kill SRA-expressing trypanosomes both in vitro 
(  3  ) and in vivo when conjugated to nanobodies directed 
against VSG carbohydrate epitopes and injected into   T. bruce  i  –
  SRA  –  infected mice (  8  ). Transgenic expression of Tr-apoL-I 
in livestock could therefore conceivably create animals that are 
resistant to infection by all species of trypanosomes. Tr-apoL-I  –
  transfected mice revealed robust expression of Tr-apoL-I that 
readily assembled into HDL particles in a manner similar to 
full-length apoL-I (  Fig. 3 A  ). To our surprise, we were un-
able to detect any lytic activity in vivo against SRA-express-
ing trypanosomes, or even against the susceptible   T. b. brucei   
(  Table II  ). To improve the potential activity of Tr-apoL-I, 
we generated a double plasmid (Hpr:Tr-apoL-I) and trans-
fected Tg-HuapoA-I mice, thereby creating HuapoA-I:Hpr:
Tr-apoL-I mice. Serial dilution of Tg mice plasma revealed 
robust expression of both proteins (  Fig. 3 B  ), which could be 
coimmunoprecipitated indicating their localization in the 
same HDL (Fig. S1). However, inoculation of mice with a 
    Figure 3.     Tr-apoL-I gene expression in Tg-HuapoA-I mice does not 
protect from infection with   T. b. brucei   or   T. b. brucei-SRA  .   (A)  A 280  
profi  le of KBr-purifi  ed lipoproteins separated by size on a Superdex 200 
column; fractions 6  –  7 are void, fractions 10  –  14 are HDLs as indicated by 
the distribution of apoA-I, and fraction 15 is albumin. (inset) A Western 
blot of the fractions probed for apoA-I (28 kD) and Tr-apoL-I (   35  kD) 
detected with polyclonal anti  –  apoL-I. (B) Western blot with serial dilutions 
of plasma from HuapoA-I mice expressing Hpr and Tr-apoL-I from a sin-
gle plasmid (HuapoA-I:Hpr:Tr-apoL-I) and normal human plasma. Hpr, 
apoL-I, and Tr-apoL-I were detected with polyclonal antibodies. (C) Mice 
expressing combination of Hpr and apoL-I in a single plasmid (black circle, 
Hpr:apoL-I;   n   = 3), Tr-apoL-I (cross,   n   = 5), combination of Hpr and Tr-apoL-I 
in a single plasmid (gray diamond; Hpr:Tr-apoL-I;   n   = 10) were infected i.
p. with 5,000   T. b. brucei   trypanosomes. Control mice were treated with 
empty vector (gray circle;   n   = 4). The parasitemia was monitored and time 
of death was recorded. (D) Mice expressing a combination of Hpr and 
apoL-I in a single plasmid (black circle, Hpr:apoL-I;   n   = 5) and a combina-
tion of Hpr and Tr-apoL-I in a single plasmid (gray diamond; Hpr:Tr-apoL-I; 
  n   = 5) were infected i.p. with 5,000   T. b. brucei-SRA   trypanosomes. Control 
mice were treated with empty vector (gray circle;   n   = 2). The parasitemia 
was monitored and the time of death was recorded.     
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minus (stop codon at 342) is suffi   cient to eliminate TLF activity 
in vivo, even though Tr-apoL-I is synthesized and incor-
porated into HDL and contains both the pore-forming and 
membrane-addressing domains. Therefore, it is unlikely that 
a transgene that encodes for this Tr-apoL-I will lead to the 
production of trypanosome-resistant transgenic animals. 
  Conclusion 
  Overall, our in vivo data show that apoL-I is necessary and 
suffi   cient to kill trypanosomes. Conversely, Tr-apoL-I, which 
was predicted to be lytic for   T. b. bruce  i  –  SRA, and therefore 
  T. b. rhodesiense  , is unable to kill any trypanosomes in vivo or 
in vitro, thereby underscoring the importance of the C-terminal 
    -helix of apoL-I in the context of HDL. Hpr expressed in 
vivo does not cause the lysis of African trypanosomes. Although 
Tg-Hpr mice have been previously described, no lytic activity 
was detected in purifi  ed HDL in vitro (  27  ), which is in agree-
ment with our data. We fi  nd that the addition of Hpr does not 
enhance the in vivo protection directly within the Tg mice, 
over and above apoL-I. Despite the observation that Hpr re-
distributes apoL-I into higher molecular mass HDLs, Hpr in 
combination with apoL-I is not suffi   cient to generate TLF 
with lytic activity that is measurable in vitro within the time 
frame of our assay. It is the combination of human apoA-I, 
Hpr, and apoL-I that recreates a fully functional   “  human TLF  ”   
in vitro, with equivalent lytic capacity to purifi  ed human TLF. 
These data lead us to conclude that all three human proteins 
are necessary to eff  ect maximal killing and emphasize the im-
portance of Tg mice to validate hypotheses generated through 
in vitro experimentation. Further use of these Tg mice, cou-
pled with the development of newly engineered lines of mice, 
should help unravel many questions associated with the in vivo 
biological properties of TLF. 
    MATERIALS AND METHODS   
  Cloning and expression of apolipoprotein L-I and haptoglobin-
related protein in individual plasmids and together in one plasmid.   
  pRG977 plasmid was obtained from Regeneron Pharmaceuticals, Inc. 
  Human haptoglobin-related protein encoding the full-length signal 
peptide (accession no.   NM_02099  5), a gift from M. Redpath (New York 
University School of Medicine, New York, NY), was cloned into pRG977 
plasmid. A Kozac sequence CCACC was introduced by site-directed muta-
genesis (Stratagene; P1). 
  A TopoTA -PCR product of apolipoprotein L-I from human liver 
(accession no.   O14791  ), gift of E. Lugli (New York University School of 
Medicine), was cloned into pRG977 plasmid (P2). The DNA sequence en-
coding the full-length signal peptide of apoL-I and a Kozac sequence CCACC 
was introduced by PCR amplifi  cation with Pfu Ultra (Stratagene) and cloned 
into pRG977 (P3). 
  A dual construct containing apoL-I and Hpr (each with their own pro-
motor, and poly[A] tail) was cloned into pRG977 (P5). Tr-apoL-I and Hpr:
Tr-apoL-I was obtained by site-directed mutagenesis of full-length apoL-I, 
P3, or the dual construct P5 by introducing a stop codon at position 342. All 
plasmids were sequenced before use. 
  Transfection of mice.     Expression of human Hpr and ApoL-I in the plasma of 
mice was achieved by performing hydrodynamics-based transfection (  16  ). Male 
Swiss Webster mice (20 g) were injected i.v., in less than 10 s, with 2 ml of sterile 
0.9% NaCl solution containing 50  –  100     g of plasmids. For expression of 
apoL-I, Hpr, or both in HDL particles containing human apoA-I, high-volume 
low dose of 5,000 parasites did not reveal any signifi  cant try-
panolytic activity (P   >   0.05) of HuapoA-I:Hpr:Tr-apoL-I 
against   T. b. brucei   (  Fig. 3 C  ) or   T. b. brucei-SRA   (  Fig. 3 D  ). 
  The discrepancy between active Tr-apoL-I generated 
in vitro and inactive Tr-apoL-I generated in vivo could be 
caused by potential diff  erences in conformation, binding, 
traffi   cking, and accumulation within trypanosomes. It is un-
known how apoL-I folds in solution when synthesized in 
bacteria in vitro compared with that present in HDL mole-
cules when synthesized in transgenic mice in vivo, but it is 
likely that the structures are diff  erent. Lipid-poor apolipopro-
teins, depending on the concentration, will form oligomers in 
physiological media, whereas apolipoproteins bound to lipid-
rich HDL particles do not (  24  ). The recombinant   “  lipid-free  ”   
Tr-apoL-I  –  nanobody binds to VSG all over the surface of the 
parasite, whereas HDL and TLF bind to specifi  c receptors in 
the fl  agellar pocket (  11, 15  ). TLF is traffi   cked to lysosomes, 
wherein it is activated (  7  ). It is unknown where the   “  lipid 
free  ”   Tr-apoL-I nanobody traffi   cs, accumulates, or acts. 
  Despite the lack of activity of Tr-apoL-I, full-length 
apoL-I bound to HDL is completely eff  ective in vivo (  Table I   
and   Fig.1  ). Coexpression with human apoA-I and Hpr in-
creases the lytic activity of full-length apoL-I that is measur-
able in vivo, by plasma transfer (  Fig. 2 B  ), and in vitro (  Fig. 2 E  ). 
In contrast, there is no signifi  cant activity of Tr-apoL-I bound 
to HDL, even when coexpressed with human apoA-I and 
Hpr (  Fig. 3, C and D  ). Therefore, the data indicate that the 
C terminus of apoL-I clearly contributes to lytic activity and 
is absolutely required when associated with HDL. 
  An individual from India was diagnosed with   T. evansi  , 
which is not normally infective for humans (  25  ). He had two 
mutated apoL-I alleles that prevented the production of func-
tional apoL-I protein. It was speculated that the lack of the 
apoL-I pore-forming domain (stop codon at aa 149) or mem-
brane-addressing domain (stop codon at 268) were key to his 
susceptibility to   T. evansi   (  26  ). In contrast, our Tg-Tr-apoL-I 
mice data show that deletion of the last     -helix at the C ter-
    Table II.        Transgenic mice that express the truncated apoL-I 
devoid of the SRA-interacting domain do not protect from 
infection with   T. b. brucei   or   T. b. brucei-SRA  
Transgenic 
  DNA
Trypanosome species 
  (1.78   ×   10  6   injected i.p.)
Number mice alive/ 
  number mice infected
Day 3 Day 50
ApoL-I   T. b. brucei 5/5 3/5  a 
Tr-apoL-I 0/5  b 
Vector 0/5  b 
ApoL-I   T. b. brucei SRA 0/5  b 
Tr-ApoL-I 0/5  b 
Vector 0/5  b 
Tg mice expressing full-length apoL-I or truncated apoL-I infected with 1.78 x10  6    T. 
b. brucei   (Lister 427-derived line) or   T. b. brucei-SRA   (Lister 427-derived line 
expressing the SRA gene).   n   = 5 per group.
  a  No parasites detectable.
  b Parasitemia   ≥   1   ×   10 9  /ml before mice were killed.JEM VOL. 205, August 4, 2008  1727
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injections were performed in C57BL/6-Tg(APOA1)1Rub/J (The Jackson 
Laboratory). Control mice were C57BL/6, which express murine apoA-I. 3 d 
after injections and every other day thereafter blood samples (20   μ  l) were taken 
from the animals via tail bleeds for evaluation of secreted human proteins. All 
procedures were approved by the Institutional Animal Care and Use Commit-
tee of the New York University Langone Medical Center. 
  Purifi   cation of lipoproteins.     HDL was purifi  ed from the plasma of two 
mice by adjusting the density to 1.25 g/ml with KBr and centrifuged for 16 h 
at 49,000 rpm at 10  °  C in NVTi65 rotor. The lipoprotein fractions were col-
lected, concentrated, and fractionated on a Superdex 200 HR 10/30 column 
(GE Healthcare) (  5  ). 
  Electrophoresis and immunoblotting.     Plasma samples or lipoprotein 
fractions were separated on 7.5% Tris-glycine PAGE Gold precast gels 
(Cambrex), transferred onto PDVF membranes (GE Healthcare), and probed 
with the following: polyclonal rabbit anti  –  human haptoglobin (1:20,000; 
Sigma-Aldrich); mouse monoclonal anti-Hpr (1:5,000); mouse monoclonal 
anti  –  apoL-I (1:10,000), polyclonal rabbit anti  –  human apoL-I (1:10,000; 
Proteintech Group, Inc.), polyclonal goat anti  –  human apoL-I (N20, 1:100; 
Santa Cruz Biotechnology), polyclonal sheep anti  –  human apoA-I (1:10,000; 
AbD Serotec), and polyclonal rabbit anti mouse apoA-I (1:10,000: Abcam). 
Secondary antibodies conjugated to horseradish peroxidase used were as fol-
lows: anti  –  rabbit IgG (1:10,000), anti  –  mouse IgG (1:50,000), anti  –  goat IgG 
(1:10,000; all Promega), and anti  –  sheep IgG (1:10,000; Roche). 
  Trypanosomes.     The following trypanosomes were used: serum-sensitive   
T. b. brucei   ILTat1.25 and   T. b. brucei   Lister 427-derived cell line, the serum-
resistant strain   T. b. brucei   427-derived cell line expressing the serum resistance-
associated (SRA) gene ( 28  ), serum-sensitive  T. evansi   (Antat 3), and  T. congolense   
(STIB68 Q). 
  In vivo experiments.     For survival experiments mice were infected i.p. 
with 1.78   ×   10  6   or 5,000 trypanosomes on day 3 after high-volume injection 
of the human genes. For plasma transfer experiments, on day 3 after transfec-
tion with human transgenes, mice were killed. Aliquots of 300   μ  l of plasma 
were injected i.v. into naive mice that were infected with   T. b. brucei   
(0.5  –  2.5   ×   10  8  /ml). Parasitemia was followed, and mice that reached para-
sitemia of 1   ×   10  9  /ml were killed and their time of death was recorded. 
  In vitro experiments.     Trypanosomes (  T. b. brucei   ILTat 1.25; 10  6  ) were 
incubated for 150 min at 37  °  C in DME, 0.2% BSA with aliquots of sized 
fractionated lipoproteins. Where indicated, parasites were incubated with 
NH  4  Cl (10 mM). Parasite lysis was determined using a calcein-AM fl  uor-
escence  –  based assay (  29  ). 
  Online supplemental material.     Fig. S1 shows that Hpr and apoL-I, as 
well as Hpr and truncated apoL-I, colocalize to the same HDL when 
immunoprecipitated with anti  –  apoL-I polyclonal antibodies. 
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